Evidence map›Paper›PMID 27353330›Full record

ArticleNucleic acids research2016

SLIRP stabilizes LRPPRC via an RRM-PPR protein interface.

Henrik Spåhr, Agata Rozanska, Xinping Li, Ilian Atanassov, Robert N Lightowlers, Zofia M A Chrzanowska-Lightowlers, Oliver Rackham, Nils-Göran Larsson

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Targeting COPA to Enhance Erdafitinib Sensitivity in FGFR-Altered Bladder Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Mitochondrial nucleic acids in innate immunity and beyond.Experimental & molecular medicine · 2023
    Review
  15. Review
  16. Article
  17. Article
  18. Human Mitochondrial RNA Processing and Modifications: Overview.International journal of molecular sciences · 2021
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 4 countries.

Henrik SpåhrDepartment of Mitochondrial Biology, Max Planck Institute for Biology of Ageing, D-50931 Cologne, Germany Spahr@age.mpg.de.
Agata RozanskaWellcome Trust Centre for Mitochondrial Research, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.
Xinping LiProteomics Core Facility, Max Planck Institute for Biology of Ageing, D-50931 Cologne, Germany.
Ilian AtanassovProteomics Core Facility, Max Planck Institute for Biology of Ageing, D-50931 Cologne, Germany.
Robert N LightowlersWellcome Trust Centre for Mitochondrial Research, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.
Zofia M A Chrzanowska-LightowlersWellcome Trust Centre for Mitochondrial Research, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.
Oliver RackhamHarry Perkins Institute of Medical Research and Centre for Medical Research, The University of Western Australia, Nedlands, Western Australia 6009, Australia School of Chemistry and Biochemistry, The University of Western Australia, Crawley, Western Australia 6009, Australia.
Nils-Göran LarssonDepartment of Mitochondrial Biology, Max Planck Institute for Biology of Ageing, D-50931 Cologne, Germany Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77 Stockholm, Sweden Larsson@age.mpg.de.
Max Planck Institute for Biology of Ageing · DENewcastle University · GBUniversity of Western Australia · AU

Funding

Wellcome Trust 096919/Z/11/Z
6 · The paper itself

Abstract

LRPPRC is a protein that has attracted interest both for its role in post-transcriptional regulation of mitochondrial gene expression and more recently because numerous mutated variants have been characterized as causing severe infantile mitochondrial neurodegeneration. LRPPRC belongs to the pentatricopeptide repeat (PPR) protein family, originally defined by their RNA binding capacity, and forms a complex with SLIRP that harbours an RNA recognition motif (RRM) domain. We show here that LRPPRC displays a broad and strong RNA binding capacity in vitro in contrast to SLIRP that associates only weakly with RNA. The LRPPRC-SLIRP complex comprises a hetero-dimer via interactions by polar amino acids in the single RRM domain of SLIRP and three neighbouring PPR motifs in the second quarter of LRPPRC, which critically contribute to the LRPPRC-SLIRP binding interface to enhance its stability. Unexpectedly, specific amino acids at this interface are located within the PPRs of LRPPRC at positions predicted to interact with RNA and within the RNP1 motif of SLIRP's RRM domain. Our findings thus unexpectedly establish that despite the prediction that these residues in LRPPRC and SLIRP should bind RNA, they are instead used to facilitate protein-protein interactions, enabling the formation of a stable complex between these two proteins.

Indexed as

Repetitive Sequences, Amino AcidRNA Recognition MotifAmino AcidsAmino Acid SequenceConserved SequenceCross-Linking ReagentsHEK293 CellsHumansModels, BiologicalMutationNeoplasm ProteinsProtein BindingProtein MultimerizationProtein StabilityRNARNA-Binding ProteinsAmino AcidsCross-Linking ReagentsLRPPRC protein, humanNeoplasm ProteinsRNARNA-Binding ProteinsSLIRP protein, human

Identifiers

PMID27353330
PMCPMC5001613
OpenAlexW2462997437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.